Immunotherapy/Chemo Combinations Show Continued Benefit in NSCLC
Published: Thursday, Jan 17, 2019
Vinay Gupta, MD
Several clinical trials have evaluated the addition of immunotherapy to standard chemotherapy in the frontline treatment of patients with advanced non–small cell lung cancer (NSCLC), explained Vinay Gupta, MD, all of which echo similar conclusions: these combinations are a mainstay in this population.
... to read the full story